Feasibility Study of Adjuvant Chemotherapy of S-1 and Carboplatin for Completely Resected Non-Small Cell Lung Cancer

被引：5

作者：

Komazaki, Yoshitoshi ^{[1
]}

Sakashita, Hiroyuki ^{[1
]}

Furuiye, Masashi ^{[1
]}

Fujie, Toshihide ^{[1
]}

Tamaoka, Meiyo ^{[1
]}

Sumi, Yuki ^{[1
]}

Miyazaki, Yasunari ^{[1
]}

Kojima, Katsuo ^{[2
,3
]}

Jin, Yasuto ^{[4
]}

Inase, Naohiko ^{[1
]}

机构：

[1] Tokyo Med & Dent Univ, Dept Integrated Pulmonol, Tokyo 1138519, Japan

[2] Tokyo Med & Dent Univ, Dept Cardiothorac Surg, Tokyo 1138519, Japan

[3] Musashino Red Cross Hosp, Dept Thorac Surg, Tokyo, Japan

[4] Hiratsuka Kyosai Hosp, Dept Pulm Med, Kanagawa, Japan

来源：

CHEMOTHERAPY | 2013年 / 59卷 / 01期

关键词：

Adjuvant chemotherapy; Carboplatin; Feasibility; Non-small cell lung cancer; NSCLC; S-1; Thrombocytopenia; VINORELBINE PLUS CISPLATIN; EXPRESSION LEVELS; PHASE-III; DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDYLATE SYNTHASE; GASTRIC-CANCER; STAGE-IB; TRIAL; PACLITAXEL; JAPAN;

D O I：

10.1159/000351101

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The purpose of this study was to evaluate the feasibility and compliance of adjuvant chemotherapy of S-1 plus carboplatin for patients with completely resected non-small cell lung cancer (NSCLC) of pathological stage IB-IIIB. Methods: S-1 was given orally at a dose of 80 mg/m(2)/day for 2 weeks, followed by a 2-week period of no treatment. Carboplatin was given intravenously on day 8 at an area under the curve of 6. This regimen was repeated for four to six 28-day courses. Results: Seventeen patients were enrolled in this study. Fourteen of them completed at least 4 cycles of chemotherapy. Nine patients had grade 2 and three patients had grade 3 thrombocytopenia, respectively. Severe nonhematologic toxicities were uncommon. Treatment was delayed in a few patients because of prolonged thrombocytopenia. Conclusion: We concluded that the regimen was feasible and tolerable for patients with completely resected NSCLC as adjuvant chemotherapy. Copyright (c) 2013 S. Karger AG, Basel

引用

页码：35 / 41

页数：7

共 50 条

[41] Adherence and Feasibility of 2 Treatment Schedules of S-1 as Adjuvant Chemotherapy in Completely Resected Lung Cancer
Kiribayashi, T.
Hata, Y.
Kishi, K.
Nagashima, M.
Nakayama, T.
Ikeda, S.
Kadokura, M.
Ozeki, Y.
Otsuka, H.
Murakami, Y.
Kusachi, S.
Takagi, K.
Iyoda, A.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1961 - S1962
[42] Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study
Yano, Tokujiro
Yamazaki, Koji
Maruyama, Riichiroh
Tokunaga, Shoji
Shoji, Fumihiro
Higashi, Hidefumi
Takeo, Sadanori
Ichinose, Yukito
Maehara, Yoshihiko
LUNG CANCER, 2010, 67 (02) : 184 - 187
[43] Efficacy of Adjuvant Chemotherapy for Completely Resected Stage IB Non-Small Cell Lung Cancer
Byun, M. K.
Park, H. J.
Park, H. S.
Jeung, H.
Cho, J. Y.
Lee, S. S.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1982 - S1982
[44] Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
Buffoni, Lucio
Vavala, Tiziana
Novello, Silvia
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (10)
[45] Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: A retrospective study in Japan
Kenmotsu, Hirotsugu
Ohde, Yasuhisa
Shukuya, Takehito
Eida, Hirofumi
Akamatsu, Hiroaki
Ono, Akira
Nakamura, Yukiko
Tsuya, Asuka
Kaira, Kyoichi
Naito, Tateaki
Murakami, Haruyasu
Takahashi, Toshiaki
Maniwa, Tomohiro
Isaka, Mitsuhiro
Endo, Masahiro
Kondo, Haruhiko
Yamamoto, Nobuyuki
RESPIRATORY INVESTIGATION, 2012, 50 (04) : 157 - 161
[46] Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer
Ganti, Apar Kishor
Williams, Christina D.
Gajra, Ajeet
Kelley, Michael J.
CANCER, 2015, 121 (15) : 2578 - 2585
[47] Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial
Hata, Yoshinobu
Kiribayashi, Takaharu
Kishi, Kazuma
Nagashima, Makoto
Nakayama, Takefumi
Ikeda, Shingo
Kadokura, Mitsutaka
Ozeki, Yuichi
Otsuka, Hajime
Murakami, Yoshitaka
Takagi, Keigo
Iyoda, Akira
BMC CANCER, 2017, 17
[48] Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809
Niho, S.
Ikeda, N.
Michimae, H.
Suzuki, K.
Sakai, H.
Kaburagi, T.
Minato, K.
Kato, T.
Okamoto, H.
Seto, T.
Hosomi, Y.
Shimizu, K.
Oshita, F.
Kunitoh, H.
Tsuboi, M.
Takeuchi, M.
Watanabe, K.
BRITISH JOURNAL OF CANCER, 2013, 109 (03) : 545 - 551
[49] Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study
Sekine, Akimasa
Satoh, Hiroaki
Baba, Tomohisa
Ikeda, Satoshi
Okuda, Ryo
Shinohara, Takeshi
Komatsu, Shigeru
Hagiwara, Eri
Iwasawa, Tae
Ogura, Takashi
Kato, Terufumi
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (06) : 1245 - 1252
[50] Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial
Noriyasu Usami
Kohei Yokoi
Yoshinori Hasegawa
Hiroyuki Taniguchi
Joe Shindo
Masashi Yamamoto
Ryujiro Suzuki
Kazuyoshi Imaizumi
Masashi Kondo
Kaoru Shimokata
International Journal of Clinical Oncology, 2010, 15 : 583 - 587

← 1 2 3 4 5 →